Amylyx Pharmaceuticals (NASDAQ:AMLX) & Revolution Medicines (NASDAQ:RVMD) Head-To-Head Contrast

Revolution Medicines (NASDAQ:RVMD) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Profitability

This table compares Revolution Medicines and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Revolution Medicines and Amylyx Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1	1	22	1	2.92
Amylyx Pharmaceuticals	1	0	7	1	2.89

Revolution Medicines presently has a consensus price target of $242.90, suggesting a potential upside of 26.97%. Amylyx Pharmaceuticals has a consensus price target of $40.71, suggesting a potential upside of 41.08%. Given Amylyx Pharmaceuticals’ higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Revolution Medicines.

Risk and Volatility

Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500.

Insider & Institutional Ownership

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Revolution Medicines and Amylyx Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13 billion	($8.82)	-21.69
Amylyx Pharmaceuticals	$87.37 million	36.80	-$144.74 million	($1.43)	-20.18

Amylyx Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amylyx Pharmaceuticals beats Revolution Medicines on 9 of the 12 factors compared between the two stocks.

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.